福元医药：关于坎地沙坦酯氢氯噻嗪片（Ⅱ）获得药品注册证书的公告

Core Viewpoint - Fuyuan Pharmaceutical has received approval from the National Medical Products Administration for the production of Candesartan Cilexetil and Hydrochlorothiazide Tablets, indicating a significant advancement in its product portfolio [1] Group 1 - The approved product is Candesartan Cilexetil and Hydrochlorothiazide Tablets, with each tablet containing 16mg of Candesartan Cilexetil and 12.5mg of Hydrochlorothiazide [1] - The product has been assigned the registration certificate number 2025S02994 [1] - This approval allows the company to commence production of the medication, potentially enhancing its market presence [1]